Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1

Am J Pathol. 1990 Jul;137(1):135-47.


In earlier studies of oncogene expression in ovarian and endometrial neoplasms, the authors reported that high tumor levels of fms-complementary transcripts correlate with high histologic grade and advanced clinical stage presentations. In this communication, they pursue these initial clinicopathologic investigations to demonstrate by in situ hybridization and immunohistochemistry that malignant epithelial cells of 14 of 14 invasive adenocarcinomas of the ovary express fms-complementary transcripts. By Northern blotting and by reverse transcription, followed by polymerase chain reaction amplification, the authors also were able to demonstrate fms transcript expression in several ovarian and endometrial carcinoma-derived cell lines. Because about half (6/14) of the invasive adenocarcinoma specimens were shown to coexpress fms and colony-stimulating factor 1, the authors propose that the expression of this lymphohematopoietic cytokine and its receptor by ovarian adenocarcinomas could contribute to their proliferative and invasive characteristics in vivo.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / analysis*
  • Adenocarcinoma / immunology
  • Colony-Stimulating Factors / analysis*
  • Female
  • Humans
  • Macrophage Colony-Stimulating Factor
  • Ovarian Neoplasms / analysis*
  • Ovarian Neoplasms / immunology
  • Polymerase Chain Reaction
  • Proto-Oncogene Proteins / analysis
  • Proto-Oncogene Proteins / genetics*
  • RNA / analysis
  • Receptor, Macrophage Colony-Stimulating Factor
  • Transcription, Genetic*


  • Colony-Stimulating Factors
  • Proto-Oncogene Proteins
  • RNA
  • Macrophage Colony-Stimulating Factor
  • Receptor, Macrophage Colony-Stimulating Factor